AZTA:NSD-Azenta Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 70.37

Change

+1.20 (+1.73)%

Market Cap

USD 5.22B

Volume

0.38M

Avg Analyst Target

USD 100.75 (+43.17%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Azenta Inc (AZTA) Stock Analysis:
Based on the Azenta Inc stock forecasts from 3 analysts, the average analyst target price for Azenta Inc is USD 100.75 over the next 12 months. Azenta Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Azenta Inc is Bullish , which is based on 8 positive signals and 2 negative signals. At the last closing, Azenta Inc’s stock price was USD 70.37. Azenta Inc’s stock price has changed by -0.51% over the past week, -7.84% over the past month and 0% over the last year.

About

Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry, and life science sample-based services and solutions for the life sciences market worldwide. The company operates in two segments, Life Sciences Products and Life Sciences Services. The Life ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-25 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

+4.19 (+1.92%)

USD79.55B 49.36 34.81
HOLX Hologic Inc

-2.39 (-3.05%)

USD19.39B 12.84 8.15
RGEN Repligen Corporation

+2.75 (+1.82%)

USD8.50B 60.65 35.23
XRAY DENTSPLY SIRONA Inc

+0.48 (+1.26%)

USD8.29B 22.90 11.38
MASI Masimo Corporation

-3.65 (-2.58%)

USD7.90B 36.76 22.65
NVCR NovoCure Limited

+2.00 (+2.72%)

USD7.76B 1,480.87 3,651.48
ICUI ICU Medical Inc

+1.13 (+0.63%)

USD4.32B 96.87 32.28
QDEL Quidel Corporation

-1.41 (-1.40%)

USD4.24B 4.29 2.21
MMSI Merit Medical Systems Inc

+0.07 (+0.12%)

USD3.43B 72.96 24.01
STAA STAAR Surgical Company

+2.08 (+3.62%)

USD2.93B 103.69 64.43

ETFs Containing AZTA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.75% 57% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.75% 57% F 39% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 5.22B 83% B 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.35 96% A 90% A-
Price/Book Ratio 1.53 80% B- 53% F
Price / Cash Flow Ratio 34.84 20% F 8% F
EV/EBITDA 418.21 12% F 2% F
Management Effectiveness  
Return on Equity -0.98% 54% F 48% F
Return on Invested Capital -0.83% 47% F 49% F
Return on Assets 0.16% 57% F 50% F
Debt to Equity Ratio 3.75% 88% B+ 81% B-
Technical Ratios  
Dividend Yield 0.57% 20% F 8% F
Short Ratio 4.61 46% F 36% F
Short Percent 3.42% 54% F 46% F
Beta 1.66 30% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.